Evidence map›Paper›PMID 38371455›Full record

ArticleInternational journal of nanomedicine2024

Nasal Administration of bFGF-Loaded Nanoliposomes Attenuates Neuronal Injury and Cognitive Deficits in Mice with Vascular Dementia Induced by Repeated Cerebral Ischemia‒Reperfusion.

Ming Zhang, Shuai-Shuai Huang, Wen-Yue He, Wei-Juan Cao, Min-Yi Sun, Ning-Wei Zhu

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. International journal of molecular sciences · 2026
    Article
  3. Genomic and proteomic conversion of brain ischemia to Alzheimer's disease.Frontiers in cell and developmental biology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ming ZhangDepartment of Pharmacy, Ningbo Yinzhou NO.2 Hospital, Ningbo, Zhejiang, 315100, People's Republic of China.
Shuai-Shuai HuangDepartment of Pharmacy, Ningbo Yinzhou NO.2 Hospital, Ningbo, Zhejiang, 315100, People's Republic of China.ORCID 0000-0001-6894-2924
Wen-Yue HeDepartment of Pharmacy, Ningbo Yinzhou NO.2 Hospital, Ningbo, Zhejiang, 315100, People's Republic of China.
Wei-Juan CaoDepartment of Pharmacy, Zhejiang Pharmaceutical University, Ningbo, Zhejiang Province, 315100, People's Republic of China.ORCID 0000-0002-4221-5101
Min-Yi SunDepartment of Pharmacy, Ningbo Yinzhou NO.2 Hospital, Ningbo, Zhejiang, 315100, People's Republic of China.
Ning-Wei ZhuDepartment of Pharmacy, Zhejiang Pharmaceutical University, Ningbo, Zhejiang Province, 315100, People's Republic of China.
Ningbo No. 2 Hospital · CNZhejiang Pharmaceutical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Basic fibroblast growth factor (bFGF) shows great potential for preventing vascular dementia (VD). However, the blood‒brain barrier (BBB) and low bioavailability of bFGF in vivo limit its application. The present study investigated how nasal administration of bFGF-loaded nanoliposomes (bFGF-lips) affects the impaired learning and cognitive function of VD mice and the underlying mechanism involved. Methods: A mouse model of VD was established through repeated cerebral ischemia‒reperfusion. A Morris water maze (MWM) and novel object recognition (NOR) tests were performed to assess the learning and cognitive function of the mice. Hematoxylin and eosin (HE) staining, Nissl staining and TUNEL staining were used to evaluate histopathological changes in mice in each group. ELISA and Western blot analysis were used to investigate the molecular mechanism by which bFGF-lips improve VD incidence. Results: Behavioral and histopathological analyses showed that cognitive function was significantly improved in the bFGF-lips group compared to the VD and bFGF groups; in addition, abnormalities and the apoptosis indices of hippocampal neurons were significantly decreased. ELISA and Western blot analysis revealed that bFGF-lips nasal administration significantly increased the concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), bFGF, B-cell lymphoma 2 (Bcl-2), phosphorylated protein kinase B (PAKT), nuclear factor erythroid 2-related factor 2 (Nrf2), NAD(P)H quinone oxidoreductase 1 (NQO1) and haem oxygenase-1 (HO-1) in the hippocampus of bFGF-lips mice compared with the VD and bFGF groups. Furthermore, the concentrations of malondialdehyde (MDA), caspase-3 and B-cell lymphoma 2-associated X (Bax) were clearly lower in the bFGF-lips group than in the VD and bFGF groups. Conclusion: This study confirmed that the nasal administration of bFGF-lips significantly increased bFGF concentrations in the hippocampi of VD mice. bFGF-lips treatment reduced repeated I/R-induced neuronal apoptosis by regulating apoptosis-related protein concentrations and activating the phosphatidylinositol-3-kinase (PI3K)/(AKT)/Nrf2 signaling pathway to inhibit oxidative stress.

Indexed as

Brain IschemiaDementia, VascularAdministration, IntranasalAnimalsApoptosisCerebral InfarctionCognitionFibroblast Growth Factor 2MiceNeuronsNF-E2-Related Factor 2Oxidative StressProto-Oncogene Proteins c-bcl-2ReperfusionFibroblast Growth Factor 2NF-E2-Related Factor 2Proto-Oncogene Proteins c-bcl-2bFGFnanoliposomesnasal administrationneuronal apoptosisoxidative stressvascular dementia

Identifiers

PMID38371455
PMCPMC10873211
OpenAlexW4392730487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.